Hostname: page-component-7b7567c8c-2rsb6 Total loading time: 0 Render date: 2026-11-12T20:59:50.482Z Has data issue: false hasContentIssue false

‘Can’tida auris’: When Candida auris can’t be controlled

Published online by Cambridge University Press:  23 June 2026

Jamil Muqtadir
Affiliation:
Rochester Regional Health
Mackenzie Kross
Affiliation:
Rochester Regional Health
German Vargas-Cuebas
Affiliation:
WRAIR | DCB | MRSN
Jennifer Gutowski
Affiliation:
Rochester Regional Health
Melissa Bronstein
Affiliation:
Rochester Regional Health
Michele Kolb
Affiliation:
Rochester Regional Health
Emil Lesho
Affiliation:
Rochester Regional Health

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Background: Candida auris (CA) poses an urgent public health threat due to its multidrug-resistance, associated mortality, and ability to persist in the inanimate healthcare environment. We sought to ascertain factors associated with a prolonged multi-facility outbreak that was not amenable to previously successful containment measures involving Clade 1. Methods: Contact tracing and testing, environmental sampling, cleaning observations with intensified cleaning, and whole genome sequencing were performed. Additionally, dry hydrogen peroxide units (Synexis DHP® Overland Park, KS) were installed, damaged furniture was replaced, and availability of dedicated equipment was increased. Standard urine culturing protocols were changed to better detect and identify yeast. Exposed patients that remained uncolonized were compared to exposed colonized patients in a nested case control exploratory analysis using multivariable logistic regression with excess antibiotic days as the primary exposure in the adjusted model. Covariates were selected based on prior understanding of the pathogen, biological plausibility, and univariable analyses to explore crude associations. We created one primary adjusted model, with additional sensitivity analyses conducted to avoid overfitting due to the small sample size and potential confounding. Model discrimination was evaluated using the area under the curve. Results: All isolates in the initial clusters were Clade III and highly genetically related to each other. Later a small cluster of highly related Clade 1 emerged. Patient variables and descriptive statistics appear in Table 1. After adjusting for age, sex, number of rooms the patient occupied, and Charlson comorbidity score, each additional day of unjustified antibiotics prior to culture was associated with a 63% increase in the odds of CA positivity (OR=1.63 per day, 95% CI: 1.22-2.53, p=0.007). Number of patient rooms occupied prior to culture was also strongly associated with positivity (OR=1.83 per additional room, 95% CI 1.37-2.82, p=0.0007). Discussion We applied the same containment measures that had previously succeeded, along with those described above, but were unable to control this outbreak. At the time of this submission, CA continued to be detected sporadically in clinical cultures, supporting our hypothesis that clade III is more difficult to contain than Clade I. This report is notable because it confirms our earlier findings of CA emergence linked solely to excess antibiotic exposure, using a more robust study design. As excess antibiotic days was independently associated with CA positivity, it underscores the importance of aggressive antimicrobial stewardship to prevent emergence. Once CA establishes itself, containment may be impossible.

A table comparing patient characteristics and variables across two groups and a total group.

A table comparing various factors related to antibacterial and antifungal exposure.

A table comparing data on SNF/LTC status, days of antibiotics prior to culture, and days of excess antibiotics between two groups.

Information

Type
Outbreaks
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America